Related Experiment Video
Updated: Feb 18, 2026
05:53
Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
10.8K
Interleukin-4 Gene Intron 3 VNTR Polymorphism in Type 2 Diabetes Patients with Peripheral Neuropathy.
Monika Buraczynska1, Kinga Buraczynska2, Pawel Zukowski1
1a Department of Nephrology , Medical University of Lublin , Lublin, Poland.
Immunological Investigations
|November 29, 2017
Summary
The interleukin-4 gene
Area of Science:
- Genetics and Molecular Biology
- Endocrinology
- Neurology
Background:
- Diabetic peripheral neuropathy (DPN) is a common complication of diabetes mellitus.
- Genetic factors may influence DPN susceptibility.
- Interleukin-4 (IL-4) plays a role in inflammatory processes relevant to diabetes complications.
Purpose of the Study:
- To investigate the association between the variable number tandem repeat (VNTR) polymorphism in intron 3 of the IL-4 gene and the risk of DPN.
- To determine if IL-4 gene polymorphism is a risk factor for DPN in type 2 diabetes mellitus (T2DM) patients.
Main Methods:
- Genotyping of the IL-4 VNTR polymorphism using polymerase chain reaction (PCR).
- Analysis of 926 T2DM patients and 420 healthy controls.
- Comparison of allele and genotype frequencies between T2DM patients with and without DPN, and in subgroups with and without cardiovascular disease (CVD).
Main Results:
- No significant association was found between the IL-4 VNTR polymorphism and DPN in the overall T2DM patient cohort.
- However, a significantly higher frequency of the P1 allele of the IL-4 VNTR polymorphism was observed in T2DM patients with DPN and coexisting cardiovascular disease (CVD) compared to those without CVD (OR 3.27, p=0.0001).
Conclusions:
- The VNTR polymorphism in the IL-4 gene is associated with DPN specifically in type 2 diabetes patients who also have cardiovascular disease.
- This finding suggests a potential gene-environment interaction involving IL-4, DPN, and CVD in T2DM patients.
More Related Videos
Related Concept Videos
01:05Single Nucleotide Polymorphisms-SNPs
18.6K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.6K
03:18Non-LTR Retrotransposons
13.5K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.5K
02:26Comparing Copy Number Variations and SNPs
18.8K
Sequencing of the human genome has opened up several best-kept secrets of the genome. Scientists have identified thousands of genome variations that exist within a population. These variations can be a single nucleotide or a larger chromosomal variation.
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
18.8K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
18
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
18